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ABSTRACT
Current mental health services across the world remain expert-centric and are based on
traditional workflows, mostly using impractical and ineffective electronic record systems or
even paper-based documentation. The international network for digital mental health
(IDMHN) is comprised of top-level clinicians, regulatory and ICT experts, genetic scientists,
and support organizations. The IDMHN has been formed to enable the implementation of
digital innovations in clinical practice, hereby facilitating the transformation of current men-
tal health services to be more personalized and more responsive to patients and healthcare
needs. This consensus statement summarizes the consortium’s vision and strategy for further
development of digital mental health.
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1. Introduction
Brain disorders represent key non-communicable dis-
eases of the 21st century: one in four people in the
world will be affected by mental or neurological dis-
orders at some point in their lives. Around 450 mil-
lion people currently suffer from such conditions,
placing mental disorders among the leading causes
of illness and disability worldwide [1]. Mental
disorders have a large impact on individuals, families,
employers and communities, and have already sur-
passed other non-communicable diseases, such as
cancer or diabetes, in terms of social and economic
burden. Global costs associated with mental disor-
ders were estimated to be e2.2 trillion in 2010 and
are expected to rise to e5.3 trillion by 2030 [2].
Mental disorders rank as the main cause of years
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lived with disabilities (YLDs): four of the six leading
causes of YLDs are due to mental disorders, includ-
ing depression, alcohol-use disorders, schizophrenia
and bipolar disorder [3]. People with mental disor-
ders also have a two- to four-fold risk of premature
mortality, with a life expectancy that is on average
25 years shorter than that of the general popula-
tion [4].
Mental health is the main medical area in which
decision making for diagnoses and treatment choice
is primarily based on clinical interviews, observations
and self-report measures. For the majority of mental
disorders, no biomarkers or technical tools have
been validated to determine diagnosis or propose
the most suitable treatment plan. The lack of useful
indicators beyond checklist diagnostic criteria is one
reason why mental disorders are often misdiag-
nosed, especially on initial presentation, particularly
if diagnostic and treatment guidelines are not used
systematically. According to recent surveys con-
ducted by GAMIAN Europe and meta-analyses, the
misdiagnosis of mental disorders is a serious prob-
lem that occurs in both primary and secondary care
mental health and in general practitioner settings:
 Sixty-nine percent of patients with bipolar dis-
order are misdiagnosed initially by mental health
specialists [5].
 On average, patients remain misdiagnosed for
5.0–7.5 years [6].
 Only 47.3% of patients with depression are cor-
rectly diagnosed by GPs [7].
As a consequence, the global gap between the
need for treatment and its provision is large. The
median time to receive a psychiatric assessment and
appropriate psychotropic medication is between 7
and 30 days in most EU countries, regardless of
symptom severity levels [8]. However, in low and
middle income countries (LMIC) between 76% and
85% of people with severe mental disorders receive
no treatment for their disorder. The corresponding
range for high-income countries (HIC) is also high
(between 35% and 50%) [9]. In addition, patients
with mental disorders have high rates of untreated
medical conditions, for example, diabetes (45%), dys-
lipidemia (88%), hypertension (62%), and smoking
(90%) [10].
2. Digital mental health
Digital technologies and a rapidly developing eHealth
field together offer novel opportunities to support
and improve mental health services, including the use
of internet-based interventions and smartphone appli-
cations that address the prevention, treatment and
aftercare of mental health problems. With economic
pressure on mental health services increasing, e-men-
tal health systems could bridge treatment gaps,
reduce waiting times for patients, and deliver inter-
ventions at lower costs. The number of mobile health
(mHealth) apps focused on mental health has rapidly
increased; a 2015 World Health Organization (WHO)
survey of 15,000 mHealth apps revealed that 29%
focus on mental health diagnosis, treatment, or sup-
port [11]. Nevertheless, despite the increasing evi-
dence base for the utility of such interventions, the
transition and implementation of these into clinical
practice is remarkably slow [12]. For example, in the
UK, only two computerized interventions for mental
health problems are recommended in clinical treat-
ment guidelines (i.e. ‘Beating the Blues’ for depres-
sion, ‘Fear Fighter’ for panic and phobia) [13,14].
Hence, it appears that amongst healthcare providers
and potential service users there are barriers to the
implementation of effective computerized interven-
tions that have not yet been fully identified or
addressed. The results of a recent study suggest that
individuals are well aware of the potential advantages
of computerized or digital interventions, but may not
place particular importance on these factors [15]. This
study highlights the need to raise awareness amongst
clinicians and service users (most likely via these clini-
cians) about the growing evidence base for digital
(including mobile) mental health interventions.
However, several factors, including poor usability, lack
of user-centric design, concerns about privacy, lack of
trust, unhelpful in emergencies, were suggested as
potential contributors to low engagement with men-
tal health apps among the patients [16]. For e-mental
health to have the large public health impact that is
often anticipated, there is need to improve the trans-
lation of eHealth research into clinical practice. Steps
towards achieving this not only include improving
awareness in clinicians and public, but also increasing
the inclusion of information on the evidence-base
and efficacy of digital mental health interventions
into clinical treatment guidelines. The other pathway
to improve user engagement with mHealth solutions
for mental health is to involve end users in the con-
ception, design and testing of apps [16].
3. DocuMental
DocuMental is a clinical decision support system
(DSS), developed by Documental Ltd (www.docu-
mental.ee) in collaboration with eHealth organiza-
tions (EIT-Health: European Institute of Innovation &
Technology; Estonian Connected Health), the
University of Tartu, and the Tallinn University of
Technology. The system is purposefully designed for
diagnosis, treatment and management of mental
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disorders, thereby providing a platform for digitized
clinical workflows in mental health. DocuMental is a
secure, web-based software tool designed for mental
health service staff, including physicians, nurses, psy-
chologists, social workers, care-coordinators and
healthcare managers. In order to improve user
friendliness and clinical workflows, DocuMental’s
leading principle is to deliver ‘immediate results’.
This aim generates added value: every step forward
is associated with results (automated documentation,
increased time-effectiveness, process and progress
overview, accuracy, error avoidance, confidence, evi-
dence-based data, etc.). To assist mental health ser-
vice, and patient as well as public needs, ultimately
resulting in better outcomes, Documental Ltd has
developed and digitized the following modules
to date:
1. Diagnostic module: consists of digitized, struc-
tured ICD-10 diagnostic criteria and ‘tick mark’
choice questionnaires for all mental health disor-
ders (From F00 to F98), including adult, adoles-
cent and childhood disorders. The ICD-10
diagnostic questionnaires are linked to DSS algo-
rithms, which provide diagnostic suggestions to
increase diagnostic accuracy and allow for diag-
nostic verification and differentiation.
2. Treatment module: consists of the whole list of
psychotropic medications, including antidepres-
sants and antipsychotics, registered in the EU for
mental health disorders, and operates via DSS
algorithms for medication- and treatment-plan
selection, including doses and regimens, drug-
drug interactions in accordance with widely rec-
ognized treatment guidelines. The treatment
module is linked to the diagnostic module and
tracks medication choices in full accordance
with clinical presentation and diagnosis, which
helps clinicians to avoid mistreatment and man-
age care plans in a standardized way. In particu-
lar, the DocuMental treatment module provides
clinicians with a list of psychotropic medications
available in the EU, guides them in their medica-
tion choices based on patient diagnosis and
presentation, and provides treatment plans in
accordance with treatment guidelines.
3. History and routine assessment modules: in
order to contribute to standardized and digitiz-
ing clinical workflows in mental health,
DocuMental has also digitized, structured and
automated history and assessment modules for
comprehensive personal and family history,
mental status, physical examination, risk assess-
ment, and optimal sets of available clinical
scales. These modules help clinicians to perform
comprehensive and standardized assessments,
which is an essential requirement for improving
disease management and personalized care.
DocuMental was selected by EIT-Health as one of
21 finalists of Business Plan Aggregator 2016 among
digital health innovations and it was the only finalist
in the mental health sector. Recently, DocuMental
has received an Estonian-Finnish Quality Innovation
Award 2017.
4. International digital mental health
network (IDMHN)
Mental health systems worldwide, in their current
traditional approach, have not yet adequately
responded to the need for more precise and person-
alized diagnosis, treatment and management of
mental disorders. To close this gap, we formed an
international network for digital mental health com-
prising top-level clinicians, regulatory and ICT
experts, genetic scientists, and support organizations
with longstanding experience and highly recognized
expertise in mental health, e-health infrastructures
and decision support systems. The first joint effort of
IDMHN was to verify and confirm the consistency of
ICD-10 diagnostic criteria for mental disorders incor-
porated in DocuMental with the original document.
Through this validation step, the IDMHN’s clinical
experts aimed to confirm that DocuMental has prop-
erly implemented ICD-10 diagnostic criteria as the
‘gold standard’ for mental disorders, and can transfer
them into routine clinical practice. The clinical
experts of IDMHN have also reviewed other modules
of DocuMental, including digitalized questionnaire
for mental status examination and pharmacological
register for treatment of mental disorders. All clinical
experts evaluated web-based DocuMental applica-
tion via personal access and reported their feedbacks
to the consortium. As they concluded, the diagnostic
criteria within DocuMental and diagnoses verified by
this DSS are in full accordance with ICD-10 original
content and diagnostic guidelines. Only minor com-
ments were made about structure and small diver-
gences in some questionnaires. All necessary
changes and additions were completed and
synchronized with ICD-10 standards and expert rec-
ommendations in the updated DocuMental version.
Generally, the clinical experts of IDMHN have found
that DocuMental ‘is well-arranged, well-engineered
and user-friendly application; its diagnostic checklists
are in accordance with ICD-10 diagnostic criteria; it
contributes to more accurate and targeted diagnosis,
and to accelerate the differential diagnosis process;
platform is intuitive, comprehensive and user-friendly
in order to conduct a complete mental status assess-
ment; implemented medication register connected
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to prescription option is well applicable for clinical
practice and helps rapid orientation in the correct
determination of treatment, i.e. clinical rules’. After
this first collaborative task, the members of IDMHN
developed the current ‘manifesto’ to summarize the
consortium’s vision and strategy for further develop-
ment of digital mental health. There is an urgent
need to improve mental disease management and
provide more precise and personalized approaches
towards better outcomes in mental health. To
achieve this goal, current mental health services and
care should be dramatically transformed and inte-
grated with novel technologies and facilities. So far,
several attempts have been made but have been
restricted to research settings; further, only some
aspects of mental health have been targeted, and it
has taken a long time to prove the concept, which
still lacks broad implementation in routine practice.
For the first time, a synergistic, multidisciplinary,
worldwide consortium have joined forces to estab-
lish a trusted, standardized and widely accepted
approach for personalized mental healthcare in rou-
tine practice and a digitized clinical workflow based
on highly promising and innovative solutions. The
main ambition of IDMHN is to become the widely
recognized lead in digital mental health, to be more
proactive in terms of connections with other medical
areas, and to be more responsive in terms of collab-
oration with authorities and organizations which rep-
resent the interests of people with mental disorders
and psychosocial disabilities. The breakthrough strat-
egy of IDMHN is in coupling of existing clinical
standards, genetic advantages and digital innova-
tions, which should result in improved, effective,
integrated and responsive mental healthcare by
establishing new clinical processes and new clinical
pathways in mental health and by enabling the
implementation of personalized approaches
in practice.
5. The IDMHN manifesto
1. Current mental health services across world are
still based on traditional workflows, mostly using
nonfunctional electronic record systems or even
paper-based documentation. For example,
according to a recent survey conducted by
University of Tartu at 17 clinical sites in 12 EU
countries: two sites are still paper-based only,
11 are using electronic health records (EHRs),
and four are using a combination of paper-
based documentation and EHRs. All clinical
sites recognized that EHRs in their current form
suffer from several limitations that hinder their
ability to meet patient needs and service
demands. In particular, current EHRs lack
decision-making functionality, are not user-
friendly, are time-consuming with regard to
data recording, have poor interdisciplinary
transferability, and suffer from insufficient data
quality and a resistance to meaningful data
tracking and searching. Based on this prelimin-
ary survey, it appears that these limited func-
tionalities are perceived by users as a serious
disadvantage in terms of data search, overview,
analyzing, transmission as well as making
appropriate and informed decisions for diagno-
sis and treatment of mental disorders.
Moreover, the lack of a system that can track
the quality of a service aggravates insufficiency
in resources and contributes to ineffective ser-
vice distribution.
2. Despite the availability of reliable and wide-
spread clinical descriptions, diagnostic guidelines
and genetic biomarkers included in clinical
guidelines (e.g. Clinical Pharmacogenetic
Implementation Consortium) and drug labeling,
rates of adherence among clinicians to these
standards remain low. One of the most serious
barriers to their utilization, beside nonfunc-
tional EHR and paper-based documentarians,
are time limitations, insufficient human resour-
ces and ‘expert-centric’ attitudes. Mental health
practitioners are required to undertake inter-
views, e.g. personal, family and health history,
and conduct comprehensive assessments, e.g.
mental status, physical health, risk assessments
and clinical scales, to reach the most appropri-
ate decisions for a possible diagnosis and treat-
ment plan, all within short consultations (about
45min for first contact and 15min for follow-
ups). As a result, very high caseloads and time
pressure may contribute to lapses in history-
taking, potential medical errors and unreliable
treatment decisions. The other challenge faced
by all countries is scarcity of specialist human
resources. The number of specialized and gen-
eral health workers dealing with mental health
is grossly insufficient. Globally, the median
number of mental health workers is 9 per
100,000 persons, but there is extreme variation
(from below 1 per 100,000 population in LMIC
to over 50 in HIC) [17]. Pressure on resources
across public services creates a powerful incen-
tive for developing new ways of delivering care
and support. Meeting rising demand and
ensuring that more people have access to
treatment and support are significant future
challenges for the mental health sector. In con-
trast to any other medical area, where diagnos-
ing and treatment plan are based on highly
sensitive and specific tests and technical
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innovations, psychiatry is still positioned as a
‘medical art’, in which initial clinical impressions
that are made by professionals usually during
first interview or observation of a patient, often
predetermine final decision in terms of diagno-
sis and treatment choice. The digital innova-
tions bringing diagnostic and treatment
standards into clinical practice and increasing
patients and their representatives’ involvement
in care plans would transform current mental
health services to be more ‘patient-centric’ and
assure the improvement of service quality via
tracking systems following compliance with
required clinical and psychosocial standards for
patients’ needs.
3. Public expectations of mental health services,
and how they might interact with them, are
changing. Through greater use of technology,
the public are becoming more engaged and bet-
ter-informed consumers of their own healthcare.
By making the most of the opportunities pre-
sented by e-mental health and digital innova-
tions, we can address some of the biggest
future resource challenges facing the mental
health sector – for example, the costs of service
delivery, workforce issues, access to services
and continuity of care. As traditional
approaches struggle to meet this overwhelm-
ing need, new technologies are required to
expand access and improve health outcomes
at lower costs. Our firm belief is that quality
improvement in mental health services, includ-
ing their ability to provide support and effect-
ively complete their responsibilities for
identification, prevention and management of
mental disorders, would significantly improve if
the highest international standards and instru-
ments orientated on achieving better outcome,
health recovery and human rights protection
are digitalized and implemented in everyday
practice. This would be performed via existing
e-approaches, including electronic record sys-
tems, online-based applications and mobile
apps, particularly those facilitating shared
therapeutic decisions between clinicians and
service users. Achieving this goal is crucially
dependent upon assuring that mental health
services routinely use the same standards
when providing treatment and support to peo-
ple with mental disorders and psychosocial dis-
abilities or needs.
4. The new concepts contributing to more precise
and personalized mental healthcare through the
integration of IT innovations, digital phenotyp-
ing, genetic approaches and cloud-based facili-
ties and technologies should improve the
management of mental disorders. The main
benefit of such an approach is the expected
shift of current, traditional mental health practi-
ces towards preventive healthcare based on
proactive assessment and screening programs
combined with early intervention and treat-
ment, instead of reactive disease treatment,
and, as result, a reduced burden on patients,
their social communities, and their healthcare
systems. The current IDMHN consortium has
proposed the joint action for development of
cloud-based Intelligent Platform for Research,
Outcome, Assessment and Care in Mental
Health (i-PROACH) enabling the wide imple-
mentation of standardized clinical processes
and pathways in mental health. We believe i-
PROACH will be established as a new inter-
nationally trusted tool for addressing societal
needs for more precise and personalized diag-
nosis, treatment and management of mental
disorder through its innovative solutions,
including clinical DSS (DocuMental software),
algorithms on genetic data (as provided by
Biobanks and genetic initiatives, for example U-
PGx: Ubiquitous Pharmacogenomics http://
upgx.eu/), digital phenotyping and artificial
intelligence tools (Figure 1). In particular, the i-
PROACH platform should promptly lead to
patients receiving more standardized and evi-
dence based care plans, less complications and
less comorbidities whilst reducing treatment
cost by avoiding unnecessary or incorrect treat-
ment medications, and provides transparent
data for monitoring and measuring outcomes,
quality of care and services provided. By facili-
tating the further integration of the i-PROACH
platform and its individual components with
other evidence-based technologies (genetic
test, neuroimaging, blood analyses etc.), the
future development of personalized medicine
approaches in mental health will be also sup-
ported in the long-term.
5. There is increased trust in cloud-based infrastruc-
tures among healthcare providers and increased
awareness that existing infrastructures within
healthcare services are insufficiently flexible for
changes and lack necessary functionalities to
address current challenges with data quality and
data exchange. In particular, the quality, access
and interoperability of existing data collected
via the majority of EHRs in mental health are
far from ideal, due to several limitations and
barriers. Generally, these data are not struc-
tured, not trackable, content-poor, and lacking
in standards and indicators. Several European
initiatives, for example BBMRI and ELIXIR,
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facilitate utilization of shared infrastructures
and services, and provide data management
technologies in open cloud-based environ-
ments, which contribute to reusable and qual-
ity data and meaningful analytical value in
mental health, especially if data are collected in
standardized and well-structured way. More
attention should be paid to high-quality (digi-
tized and standardized), reusable (interoperable
and real-time updated), and large multidiscip-
linary (e.g. clinical, demographic, psychosocial,
digital phenotyping, genetics) data collection,
handling and access in international mental
healthcare and services. It also requires compli-
ance with regulatory processes, including data
safety, privacy protection in line with the
General Data Protection Regulation (GDPR)
requirements and Digital Single Market policies,
where appropriate. As the first stage, we are
planning to elaborate the strategy for process-
ing data to European Open Science Cloud
(EOSC) services to enable the i-PROACH imple-
mentation process when integrating the i-
PROACH platform with existing e-infrastructures
and cloud-based environments across EU coun-
tries. We will establish dialog between actors
involved in official agreements and resource
allocation and proceed with legalization proc-
esses to enable the integration of i-PROACH
with healthcare databases and systems; data
hosting at local data storage services and fur-
ther transfer of research data (anonymized or
de-identified) to i-PROACH cloud.
6. Access and integration of health-related data
from multiple sources create unprecedented
opportunities for increasing the quality of health-
care by generating, integrating and managing
health data from heterogeneous sources when
healthcare providers are enabled to share part of
their data with the different stakeholders
involved in the provision of health services to
patients. The important issues in the i-PROACH
project regarding the GDPR are principles for
processing personal data, especially health-
related data, consent management and
anonymization, accountability and data govern-
ance, data protection by design and default,
data exchange, security measures and data
processors. We will analyze the impacts of
these issues on the digitalization of health pro-
fessionals’ workflows and sharing of sensitive
data across the EU, and will explore security
mechanisms like blockchain and new anonym-
ization models like controlled access and
implement solutions which enable the manage-
ment of information privacy and trust in the
networks accordingly to the GDPR principles.
We also aim to establish a data management
plan (DMP) to present rules and guidelines for
the management of personal sensitive and
non-sensitive data and ensure compliance with
European and national regulations including
data security ethical issues. To support the data
management and processing within the i-
PROACH platform, we intend to develop secure
cloud-based solutions, allowing users to run
applications processing sensitive data in a
secure environment. It would facilitate collect-
ing international or cross-border data into the
same data catalog with access to secure proc-
essing environment, supporting efficient large
analyses, required for research and administra-
tive evaluations.
Figure 1. i-PROACH platform.
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7. In the context of improving access to care and
service quality, WHO recommends the develop-
ment of comprehensive community-based mental
health and social care services; the integration of
mental health care and treatment into general
hospitals and primary care; continuity of care
between different providers and levels of the
health system; effective collaboration between
formal and informal care providers; and the pro-
motion of self-care, for instance, through the use
of electronic and mobile health technologies [9].
A substantial and increasing proportion of peo-
ple with mental disorders are being seen by
GPs or in community-based settings and in pri-
vate practice. All of these areas lack specific
digital platforms for mental health. We thus
aim to provide comprehensive, integrated and
responsive mental health services in commu-
nity-based and primary care settings. This can
be achieved by integration of the i-PROACH
platform with social and primary care services
and by providing support to increase confi-
dence and skills among non-specialized health
workers in recognizing and managing mental
disorders. The i-PROACH platform may contrib-
ute to shifting the focus of care away from
long-stay hospitalization in mental-health insti-
tutions towards non-specialized health settings,
with increasing coverage of evidence-based
interventions (including the use of stepped
care principles, as appropriate) for priority con-
ditions, and using a network of linked commu-
nity-based mental health services (including
short-stay inpatient care, and outpatient care in
general hospitals, primary care, comprehensive
mental health centers, day care centers) to sup-
port people with mental disorders living with
their families and in supported housing. This
strategy will facilitate the resource savings and
reorganization of mental health services by
reducing administrative, human and time-
related costs, and improving management and
care plans, including hospitalization length and
number of visits.
8. The i-PROACH platform may provide unique
opportunities for clinical research and scientific
programs and contribute to increased research
activity at local, national and international levels
in mental health, particularly due to inter-
national standards, and support data-searching
facilities and possible interconnectedness with
other interdisciplinary technologies. In line with
the Mental Health Action Plan 2013–2020 [9],
i-PROACH may contribute to improvements in
research capacity and academic collaboration
on national priorities for research in mental
health. In particular, the i-PROACH platform is
designed to collaborate with existing research
projects, such as PerMed for the implementa-
tion of systems and personalized medicine in
Europe, the European Alliance for Personalized
Medicine, and international organizations, such
as the Global Alliance for Genomics and Health
and the BBMRI and ELIXIR bioinformatics infra-
structures, in order to ensure maximal impact.
Furthermore, by accumulating large quantities
of detailed data about individual patients and
through the development of genetic and pre-
dictive models, the i-PROACH may also support
initiatives of biotechnology partners to collect
comprehensive data on the safety, efficacy, and
effectiveness of innovative medicines, and the
development of new, personally ‘tailored’
drugs. Due to the standardized and digitized
clinical workflow in mental health across world-
wide countries we will also facilitate real-time
search of potential patient participants for
research studies, which should reduce costs
and increase feasibility in practice. Overall, i-
PROACH will conduct research in collaboration
with multidisciplinary teams with expertise,
resources and research capacities to achieve
the critical mass needed to complete the
expected research and move towards the com-
mon goal of promoting the preservation of
health and preventing the onset of disease. We
also aim to expand i-PROACH’s involvement in
scientific and academic activities to become
the most powerful, international platform for
the promotion of research in mental health
and for the more effective use of necessarily
limited resources. The i-PROACH platform also
aims to support equity for countries with low
or middle income in obtaining resources, and
to secure their involvement in research and
consortium programs.
9. Mental health strategies and interventions for
treatment, prevention and promotion must be
based on scientific evidence and best practice,
and therefore should implement the principles
for more precise and personalized approaches in
routine management and care of mental disor-
ders. To achieve this goal, we are aiming to
establish a process of scientific validation for e-
mental health innovations, including i-PROACH
platform considering the following sequence
before full implementation: Feasibility/Pilot
(Evaluating retention/acceptability, safety, satis-
faction) followed by a Randomized Controlled
Trial either against treatment as usual or a
non-inferiority trial vs. an evidence-based inter-
vention. An implementation feasibility study
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could be the final part of the process in order
to assess large-scale feasibility. Furthermore,
the improvements in mental disease manage-
ment and mental healthcare outcomes that
result from the transformation of traditional
models of care, patient journeys and clinical
pathways to the new personalized and pre-
dictor-based digitized clinical workflows should
be evaluated by applying health impact and
the cost-effectiveness analyses. This is particu-
larly important considering the considerable
social and economic burden due to mental
health disorders. As the first pilot the economic
impact of implementing personalized mental
health approach provided by i-PROACH will be
evaluated in Estonian healthcare systems
(Figure 2). With the Estonian National Health
Information System (ENHIS) in place (used by
all Estonian healthcare providers, who are obli-
gated to forward medical data to ENHIS),
innovative programs towards personalized
medicine, a national digital prescription system,
and an established state-of-the-art genome
center, Estonia, with its modern and relatively
simple health system, is particularly suitable to
pilot i-PROACH in routine clinical practice and
implement it fully on a national scale. During
this pilot, we will be able to demonstrate and
establish interoperability between i-PROACH
platform and existing healthcare systems,
including EHRs, ENHIS, the patient portal,
digital prescriptions and the Estonian Biobank;
and to elaborate models for 1) health impact
analysis: based on direct patient level out-
comes (such as relapse rate and quality of life
within-normal) and indirect indicators (such as
hospitalization length, re-admission/presenta-
tion rates), and 2) the cost-effectiveness ana-
lysis: based on direct costs of using healthcare
services, costs for developing, implementing
and maintaining digital solutions, and costs for
training healthcare staff.
10. Despite the prioritization of mental health by the
WHO as medical area which requires more atten-
tion and transformation, this field is still signifi-
cantly less funded by grant resources, such as
European Commission or EIT-Health, than, for
example, oncology or cardiology. Psychiatric
consortia aiming to bring innovations into
mental health often face questioning attitudes
in experts involved in application review. This
is reflected by the low number of successful
and funded projects on digital mental health
led by psychiatrists. The project revision sys-
tems need more transparent and fair
approaches, with better opportunity for bilat-
eral feedback and communication on individual
projects. As recognition of this problem, EIT-
Health recently made a very significant step
towards improvement in their evolution pro-
cess of submitted applications by increasing
decision based on project face-to-face hearing
rather than based on remote expert review.
Such changes give more chance to research
teams to explain project details in better way
than it might be done in writing form. Our
multidisciplinary consortium has the required
skills and expertise through worlds leading sci-
entists in clinical research and ICT/eHealth to
explore and exploit innovations and strategies
for digital personalized mental health. We are
confident that i-PROACH will improve
Figure 2. i-PROACH implementation into routine practice.
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personalized mental health and care beyond
the current ‘state-of-the-art’ – it is ambitious,
but also realistic and achievable. To increase
recognition of our consortium and its potential
in innovation and research for mental health,
we will establish closest possible collaborations
with key stakeholders in healthcare and pro-
mote our vision through proactive involvement
in calls and actions related to digital and per-
sonalized medicine.
11. Due to digitalized and integrated international
standards for assessment and treatment of men-
tal disorders, i-PROACH represents a promising
tool for teaching, education and revalidation of
mental health workers and medical students. In
particular, we aim to implement education
activities tailored to the needs and interests of
the target groups. The activities would include:
(1) consortium website: to provide the results
of the i-PROACH progress, information about
upcoming conferences the IDMHN will attend,
and available publications; (2) policy events: to
increase collaboration with authorities and pol-
icy makers, etc., (3) peer-reviewed publications:
to facilitate the distribution and uptake of i-
PROACH results; (4) presentations at conferen-
ces: to present research results at established
international conferences by professional soci-
eties; (5) guidelines: we plan to develop i-
PROACH guidelines to guide clinicians in pre-
venting certain outcomes, such as relapse,
somatic risks, adverse side effects of drugs,
drug-drug interactions, etc. by using platform.
Planned educational materials will be available
to all interested parties through the website.
The following training activities to facilitate the
innovation and implementation of i-PROACH
for personalized mental health will include: (1)
i-PROACH User Manual; Tutorials; and Videos;
(2) i-PROACH online training: we aim to design
an online training class consisting of modules
based on the most common user activities of
the i-PROACH platform. Healthcare providers
would be able to sign up for free and try out
the different functionalities without having an
implemented platform available in their institu-
tion. This will help future users to prepare for
the implementation of the platform in their
work and will also help interested future users
to get a feel for how the platform may posi-
tively influence their clinical workflow.
Furthermore, the service users involvement
(PPI) in the further development and imple-
mentation of i-PROACH platform will be also
encouraged in order to optimize the
acceptability.
12. To maximize the impact of the i-PROACH project
we will establish strategy based on stakeholder
involvement and target-group orientation, includ-
ing patient representatives, particularly GAMIAN,
authorities and policy makers, etc. The proposed
target-group orientation will allow us to define
and implement measures geared to the specific
needs of the different groups. The i-PROACH
platform will implement dissemination activities
tailored to the needs and interests of the tar-
get groups. As the main focus of dissemination
is on the distribution and uptake of results,
most activities will focus on the scientific com-
munity, healthcare providers and policy makers.
Through an established international network,
we will introduce i-PROACH solutions to key
stakeholders and thus to expand engagement
with our project. In particular, the members of
team and partners are involved in scientific
and management boards at several inter-
national organizations and thus may help to
maximize the visibility of i-PROACH project and
platform to broad audience. We also aim to
increase collaboration with patients, authorities,
professional organizations (such as European
Psychiatric Association, World Psychiatric
Association, World Federation of Societies of
Biological Psychiatry, World Congress on
Medical Informatics and others), policies mak-
ers, eHealth experts in plans and strategies for
i-PROACH. The eHealth and ICT-oriented tech-
nology and business meetings will also help to
introduce the platform and facilitate contact
with potential major industry and investors. We
aim to develop a detailed plan for horizontal
and vertical knowledge dissemination, to
ensure that awareness of the i-PROACH project
is disseminated widely and freely available
among local and international stakeholders,
including governmental and non-governmental
organizations, commercial companies, research-
ers, clinicians, policy makers and the public.
Additionally, in close collaboration with
European and national medicine agencies the
IDMHN also reviews and adjusts the list of
medications registered for mental health to
their local availability in order to aid the
adequate choice of medicines via i-PROACH
platform for each involved country.
13. Digital solutions have the potential to reorganize
current healthcare systems by bringing new serv-
ices, influencing policies impacting personalized
healthcare approaches, and developing reim-
bursement that would be favorable for the
implementation of personalized medicine.
Conversely, such strategy in mental health
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would prevent numerous serious adverse
events and thus save resources, which will
lower the costs of the respective healthcare
systems. The complexity of the scenario
requires thorough health economical evalua-
tions, such that the results of i-PROACH would
not only provide conclusive evidence of
improved patient outcomes but also document
simultaneously the costs of healthcare.
Thereby, i-PROACH should further facilitate the
incorporation of personalized health care meas-
ures into national and international guidelines
and change clinical practice. The economic
impact of i-PROACH is potentially huge – early
identification of at risk individuals (prevention
of disease), personalized approach and increase
adherence to intervention, early and effective
treatment will reduce burden of disease, com-
plications associated with chronic diseases as
well as related treatment and hospitalization
costs, thus reducing the burden of morbidity
and mortality to society. For example, a Danish
randomized controlled trial of CYP2D6/
CYP2C19 found that pharmacogenetic testing
in patients with schizophrenia significantly
reduced costs among the extreme metabolizers
(poor metabolizers and ultrarapid metaboliz-
ers), including costs of psychiatric care, primary
care services and pharmaceuticals. This study
demonstrated an excess of costs in extreme
metabolizers ranging 177–239% higher than
‘normal’ metabolizers; when using genotype-
guided treatment, however, this excess cost
was reduced by 23–48% [18]. In addition, a
recent multicentre, randomized controlled trial
showed that compared with usual care, an
intervention based on personal predictors of
risk of depression implemented by GPs is a
cost-effective strategy to prevent depression
[19]. Thus preliminary evidences of cost savings
provides further support to the implementation
of digital solutions into clinical guidelines and
practice. Therefore, the detailed cost-effective-
ness analyses will also need to convince health
insurance companies and related organizations
to reimburse and support the clinical applica-
tion of the new strategy and digital innovations
in mental health. Considering that i-PROACH
platform potentially has a very broad imple-
mentation range, covering different ‘market
areas’ and involving a diverse community of
users, it must also be competitive priced and
qualify for the same level of reimbursement. In
particular, the business scheme for DocuMental
is planned as a subscription-based licensing
model, where price calculation will take into
account the number of users, utilization of
services, regional economic conditions, copy-
rights and permission expenses, upgrades,
technical support and profit. However, the
main principle of DocuMental and other
licensed components of the i-PROACH platform
is in immediate value for mental healthcare
and users, where expenses on subscription of
digital innovations should be significantly less
than total outcome and benefits raised by their
implementation in everyday clinical practice.
6. Summary
It is widely recognized and generally accepted that
existing standards for identification and manage-
ment of mental disorders, including diagnostic and
treatment guidelines as well as polices for human
rights protection should be applied and strictly fol-
lowed world-wide. The current international consor-
tium aims to implement i-PROACH principles into
everyday practice within a range of geographically
and socioeconomically diverse countries in order to
improve identification, management and prevention
of mental disorders via digitized and personalized
approaches, and to contribute to overall improve-
ments in mental health services. The breakthrough
approach of i-PROACH is in coupling these standards
and eHealth innovations, which results in improved,
effective, integrated and responsive mental health
sectors through enabling the implementation of
standardized instruments in practice. This approach
has a high potential to address current needs in
mental health, to become more transparent in terms
of service access and quality, to be more beneficial
in terms of outcomes and burden reduction, more
proactive in terms of connection with other areas,
and more responsive in terms of collaboration with
authorities and organizations representing the inter-
ests of people with mental disorders and psycho-
social disabilities.
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